Clinical Trial Update: Safety and Efficacy Study of LUM001 (Maralixibat) With a Drug Withdrawal Period in Participants With Alagille Syndrome (ALGS) [Phase 2]

View source ↗

Summary

Phase 2 safety and efficacy study of LUM001 (maralixibat) in participants with Alagille Syndrome has completed and results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alagille Syndrome

Drugs mentioned

• LUM001

Snippet

Sponsor: Mirum Pharmaceuticals, Inc. | Conditions: Alagille Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2021-07-14